EGFR and lung cancer: Notably, the proportional distribution exhibits geographical variation: Our cohort demonstrated significantly higher lung cancer-derived MC incidence (86.60%), potentially attributable to China’s elevated lung cancer burden (11) and the widespread therapeutic implementation of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (12).